MTOR and neoplasm: Indeed, combinations of targeted agents, including those involving mTOR inhibitors, are usually more toxic than monotherapy alternatives, requiring the administration of grossly reduced single-agent doses, thus potentially compromising anti-tumor activity; on the other hand, the functional effects of a given combination may either be synergistic or antagonistic, depending on the specific molecular context of the individual tumor.